Skip to main content

Table 2 Antibacterial activity of the target compounds 5a–5z against Xoo and Xoc

From: Design, synthesis, and biological activity of novel 1,2,4-oxadiazole derivatives

Compounds

Xoo

Xoc

50 µg/mL (%)

EC50 (µg/mL)

50 µg/mL (%)

EC50 (µg/mL)

5a

13.50 ± 3.33

NT

17.20 ± 1.60

NT

5b

0

NT

0

NT

5c

29.00 ± 3.90

NT

20.40 ± 1.00

NT

5d

0

NT

0

NT

5e

0

NT

0

NT

5f

6.70 ± 4.30

NT

12.60 ± 1.10

NT

5 g

0

NT

0

NT

5 h

10.10 ± 3.20

NT

11.30 ± 5.30

NT

5i

10.90 ± 1.00

NT

19.40 ± 2.10

NT

5j

42.17 ± 1.39

74.70 ± 5.46

41.37 ± 5.42

88.47 ± 4.21

5 k

30.59 ± 3.19

85.30 ± 3.66

15.58 ± 2.84

199.65 ± 18.98

5 l

14.16 ± 2.93

129.15 ± 11.16

29.95 ± 3.57

172.18 ± 13.94

5 m

65.85 ± 3.32

36.25 ± 1.77

33.01 ± 3.23

76.35 ± 4.82

5n

42.77 ± 2.13

56.75 ± 5.98

53.73 ± 3.24

50.93 ± 8.07

5o

26.94 ± 0.65

122.80 ± 7.32

31.60 ± 5.28

108.27 ± 5.99

5p

11.99 ± 1.18

225.35 ± 8.03

64.53 ± 3.42

31.40 ± 2.07

5q

43.78 ± 2.02

63.32 ± 1.58

33.61 ± 4.13

123.34 ± 8.55

5r

71.89 ± 1.56

24.14 ± 2.72

48.53 ± 1.66

51.11 ± 3.05

5 s

26.30 ± 2.37

95.12 ± 14.87

30.28 ± 2.88

116.76 ± 13.97

5t

38.16 ± 2.27

102.45 ± 5.99

50.37 ± 3.23

56.50 ± 6.26

5u

64.97 ± 3.46

28.82 ± 2.25

65.10 ± 4.12

19.04 ± 2.13

5v

85.37 ± 1.46

19.44 ± 2.22

64.59 ± 4.43

21.78 ± 2.82

5w

40.60 ± 3.95

75.61 ± 2.21

40.12 ± 3.23

75.22 ± 3.93

5x

61.97 ± 0.92

25.37 ± 6.98

40.29 ± 3.84

101.96 ± 5.81

5y

78.44 ± 5.54

28.52 ± 3.14

20.63 ± 6.75

125.57 ± 15.77

5z

44.07 ± 2.36

66.51 ± 5.53

53.70 ± 3.73

55.32 ± 2.96

BMT

35.12 ± 2.72

77.46 ± 6.15

45.56 ± 5.76

68.50 ± 7.87

TDC

25.12 ± 3.31

99.31 ± 7.59

37.58 ± 2.84

91.05 ± 8.84

  1. Average of three replicates
  2. NT not tested